Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04172493 · ClinicalTrials.gov registry record · NA
Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients
A NA study of Patient, sponsored by OHSU Knight Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT04172493 is a NA study of Patient that has completed, run by OHSU Knight Cancer Institute. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04172493, a NA study of Patient, has completed, sponsored by OHSU Knight Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies whether hyperspectral endoscopy improves visualization of abnormal tissue in average risk patients during standard-of-care colonoscopies. Hyperspectral endoscopy is an emerging technique that has the potential to enable the signals from blood to be resolved from tissue-specific signals. Image-enhanced endoscopy may improve visualization of abnormal colonic tissue when compared to the standard-of-care high-definition white light endoscopy.
Conditions Studied
Interventions
- PROCEDURE Hyperspectral Endoscopy (HySE)
- DEVICE White Light Endoscopy (WLE)
Study Locations (1)
Oregon
- OHSU Knight Cancer Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2019-08-26 |
| Est. Completion | 2020-01-27 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04172493
The ClinicalTrials.gov registry entry for NCT04172493 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OHSU Knight Cancer Institute, which has 211 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patient appearing as the primary indexed condition, and to 2 interventions - of which Hyperspectral Endoscopy (HySE) is the first listed.
NCT04172493 reports 1 study location spanning 1 distinct geographic area - top geographies include Oregon.
Frequently Asked Questions
What is clinical trial NCT04172493 about?
NCT04172493 is a clinical study titled "Hyperspectral Endoscopy Imaging for the Early Detection of Precancerous Lesions in Average Risk Patients". This trial studies whether hyperspectral endoscopy improves visualization of abnormal tissue in average risk patients during standard-of-care colonoscopies. Hyperspectral endoscopy is an emerging technique that has the potential to enable the signals from blood to be resolved from tissue-specific si...
What is the current status of trial NCT04172493?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2019-08-26. Estimated completion is 2020-01-27.
What conditions does trial NCT04172493 study?
This clinical trial studies the following conditions: Patient.
What interventions are being tested in trial NCT04172493?
The interventions under investigation include: Hyperspectral Endoscopy (HySE) (PROCEDURE), White Light Endoscopy (WLE) (DEVICE).
Who is sponsoring clinical trial NCT04172493?
This trial is sponsored by OHSU Knight Cancer Institute, which has 211 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04172493 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Patient
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.